Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID.

We assessed primary cutaneous large B-cell lymphoma, leg type (PCLBCL, leg type; n = 13), and primary cutaneous follicle center lymphoma (PCFCL; n = 19) for somatic hypermutation (SHM) of BCL6, and aberrant SHM of MYC, RhoH/TTF, and PAX5. We demonstrate SHM of BCL6 in 8 PCLBCLs (62%), leg type, and 7 PCFCL patients (37%), and aberrant SHM in PAX5, RhoH/TTF, and/or MYC in 7 PCLBCLs (54%), leg type, and 10 PCFCL patients (53%). The majority of mutations consisted of single base-pair substitutions (n = 54) with rare deletions/insertions (n = 4), and displayed molecular features typical of the SHM process. Quantitative real-time PCR and immunohistochemical stainings for activation-induced cytidine deaminase, which is indispensable for SHM, demonstrated significantly higher expression in PCLBCL, leg type. Our results suggest that (aberrant) SHM may contribute to the pathogenesis of PCLBCL, leg type, and PCFCL and is not restricted to diffuse large B-cell lymphomas with an aggressive clinical behavior.

[1]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[2]  Remco Dijkman,et al.  Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. , 2005, Blood.

[3]  B. Jungnickel,et al.  Differential expression of activation‐induced cytidine deaminase (AID) in nodular lymphocyte‐predominant and classical Hodgkin lymphoma , 2005, The Journal of pathology.

[4]  L. Pasqualucci,et al.  Expression of the AID protein in normal and neoplastic B cells. , 2004, Blood.

[5]  Ash A. Alizadeh,et al.  AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity , 2004, Leukemia.

[6]  M. Nussenzweig,et al.  AID Is Required for c-myc/IgH Chromosome Translocations In Vivo , 2004, Cell.

[7]  R. Willemze,et al.  Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sézary Syndrome Identified by Gene Expression Analysis , 2004, Cancer Research.

[8]  Y. Matsuo,et al.  Expression of Activation-Induced Cytidine Deaminase (AID) in Burkitt Lymphoma Cells: Rare AID-Negative Cell Lines with the Unmutated Rearranged VH Gene , 2004, Leukemia & lymphoma.

[9]  L. Pasqualucci,et al.  Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. , 2003, Blood.

[10]  R. Bende,et al.  Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype. , 2003, Cancer research.

[11]  W. Klapper,et al.  Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. , 2003, Blood.

[12]  R. Wall,et al.  Somatic hypermutation of the B cell receptor genes B29 (Igβ, CD79b) and mb1 (Igα, CD79a) , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[14]  H. Jacobs,et al.  Towards an understanding of somatic hypermutation. , 2001, Current opinion in immunology.

[15]  V. Diehl,et al.  Somatic Mutation of the Cd95 Gene in Human B Cells as a Side-Effect of the Germinal Center Reaction , 2000, The Journal of experimental medicine.

[16]  A. Fischer,et al.  Activation-Induced Cytidine Deaminase (AID) Deficiency Causes the Autosomal Recessive Form of the Hyper-IgM Syndrome (HIGM2) , 2000, Cell.

[17]  T. Honjo,et al.  Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme , 2000, Cell.

[18]  L. Pasqualucci,et al.  Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. , 2000, Blood.

[19]  P. Isaacson,et al.  Nonimmunoglobulin gene hypermutation in germinal center B cells. , 1999, Blood.

[20]  L. Pasqualucci,et al.  BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  U. Storb,et al.  Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. , 1998, Science.

[22]  Klaus Rajewsky,et al.  Somatic hypermutation in normal and transformed human B cells , 1998, Immunological reviews.

[23]  K. Rajewsky.  Clonal selection and learning in the antibody system , 1996, Nature.

[24]  M. Raffeld,et al.  Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. , 1993, Oncogene.

[25]  I. Magrath,et al.  Point mutations in the c–Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas , 1993, Nature Genetics.

[26]  R. Wall,et al.  Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a). , 2003, Proceedings of the National Academy of Sciences of the United States of America.